This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0326U only for Guardant360® from Guardant Health Inc. The test uses a next–generation sequencing (NGS) targeted sequence analysis panel to evaluate cell–free circulating DNA from a blood specimen for 83 or more genes associated with solid–organ neoplasms.
For clinical responsibility, terminology, tips and additional info
start codify free trial.